Leading vaccine producers in China 2020, based on lot release contract price
In 2020, Merck Sharp & Dohme generated more than 13 billion yuan of revenue with its vaccine products in China. The company performed better than any other vaccine producers in the country, thanks to its highly effective 4-valent and 9-valent human papillomavirus (HPV) vaccines, priced at 798 yuan and 1,298 yuan respectively. The revenue of Sinopharm subsidiaries, including Beijing Institute of Biological Products, Shanghai Institute of Biological Products, and Chengdu Institute of Biological Products, was generated by the large production volumes of mostly Class I vaccines, which were universally covered by the mandatory and free vaccination programs of the Chinese government.